Mainstay Medical Wins First ReActiv8 Neurostimulation Implant Sale

Mainstay Medical has sold its first ReActiv8 neurostimulator implant in Germany. The implant was performed by an orthopedic surgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz, Germany.

ReActiv8
Mainstay Medical has made the first sale of its ReActiv8 device • Source: Mainstay Medical

Mainstay Medical International PLC has won its first sale of ReActiv8, an implantable neurostimulation system to treat disabling chronic low-back pain (CLBP), some seven months after gaining CE mark approval. The ReActiv8 implant was performed at the Catholic Hospital Koblenz-Montabaur in Koblenz, Germany, by orthopedic surgeon Dr. Francis Kilian.

ReActiv8 is a small implanted device that electrically stimulates the nerves responsible for contracting the key muscles of the lumbar...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Surgery

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.